Although cancer therapies have evolved in the last 50 years, still today, as researchers, we face the challenge of achieving more effective treatments for this family of diseases. The main problem of traditional therapies is their toxicity and the development of resistance. Even though most therapies are targeted to specific tumor cell pathways, many are effective against the tumor bulk, but do not eliminate infiltrating immune cells or cancer stem cells that are key players in progression and recurrence. In this context, nanotechnology is a promising tool to delineate new therapeutic strategies, since it allows to tackle several targets simultaneously.
In the NanoBio laboratory of the INS we work interdisciplinary in the design of multifunctional nanoparticles based on two axes: 1) expertise in the design and synthesis of multifunctional nanoparticles; 2) solid knowledge of the mechanisms involved in tumor progression.
The goal of this team is the development of therapies that target different key players within the tumor, decreasing systemic toxicity, and eliminating the cells responsible for tumor progression and recurrence.
Group leader
Marina Simian
CONICET Superior Researcher
Posdoctoral fellow
Lilian Castillo
Marina Simian
Group Leader
CONICET Independent Researcher.
She has a Biology Sciences PhD in the University of Buenos Aires and also a doctoral working at the Lawrence Berkeley National Laboratory, in the United States.
Mail: msimian@unsam.edu.ar